SCHEMBL5802530

SCHEMBL5802530

Cc1cccc(NC(=O)Nc2ccc(-c3nn(C4CCN(C(=O)OC(C)(C)C)CC4)c4ncnc(N)c34)cc2F)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LCK P06239 9/20 0.54
▸ KDR P35968 5/20 0.54
▸ SRC P12931 5/20 0.54
▸ TEK Q02763 1/20 0.54
▸ EGFR P00533 2/20 0.51
▸ AURKA O14965 1/20 0.51
▸ IKBKE Q14164 1/20 0.51
▸ AURKB Q96GD4 1/20 0.51
▸ KIT P10721 1/20 0.51
▸ FLT3 P36888 1/20 0.51
▸ PIK3CD O00329 1/20 0.51
▸ ABL1 P00519 1/20 0.51
▸ HCK P08631 1/20 0.51
▸ PIK3CA P42336 1/20 0.51
▸ PIK3CB P42338 1/20 0.51
▸ MTOR P42345 1/20 0.51
▸ PIK3CG P48736 1/20 0.51
▸ EPHB4 P54760 1/20 0.51
▸ PRKDC P78527 1/20 0.51
▸ PI4KB Q9UBF8 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6431567 0.90 LCK (0.57) LCKKDRSRCTEKEGFR
SCHEMBL6433914 0.90 LCK (0.49) LCKKDRSRCTEKEGFR
SCHEMBL5801348 0.89 ABL1 (0.57) LCKKDRSRCEGFRPIK3CD
SCHEMBL6434464 0.88 LCK (0.56) LCKKDRSRCTEKEGFR
SCHEMBL6431538 0.87 LCK (0.53) LCKKDRSRCTEKEGFR
SCHEMBL6430834 0.87 LCK (0.53) LCKKDRSRCTEKEGFR
SCHEMBL12120718 0.87 AURKB (0.60) LCKKDRSRCTEKEGFR
SCHEMBL12120717 0.87 AURKB (0.60) LCKKDRSRCTEKEGFR
Hydrochloric Acid SCHEMBL6431342 0.87 LCK (0.56) LCKKDRSRCTEKEGFR
SCHEMBL5804562 0.86 AURKA (0.56) LCKKDRSRCTEKEGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1385524-A4 PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS ABBOTT GMBH & CO KG (DE) 2006-02-01 — — EP disclosed
US-6921763-B2 Pyrazolopyrimidines as therapeutic agents ABBOTT LABORATORIES (US) 2005-07-26 — — US disclosed
EP-1385524-A1 PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS Abbott GmbH & Co. KG (DE) 2004-02-04 — — EP disclosed
US-6660744-B1 Kinase inhibitors ABBOTT GMBH & CO. KG (DE) 2003-12-09 — — US disclosed
EP-1212327-B1 PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS BASF AG (DE) 2003-08-20 — — EP disclosed
US-20020156081-A1 Pyrazolopyrimidines as therapeutic agents ABBOTT LABORATORIES (US) 2002-10-24 — — US disclosed
WO-2002080926-A1 PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS ABBOTT GMBH & CO. KG (DE) 2002-10-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020156081-A1 Pyrazolopyrimidines as therapeutic agents DPYD, CYP2D6, UGT1A1 LCK 1011/4885KDR 1166/4885SRC 1834/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback